Literature DB >> 12116034

Vaginal dysplastic lesions in women with hysterectomy and receiving radiotherapy are linked to high-risk human papillomavirus.

Luisa Barzon1, Sergio Pizzighella, Luigi Corti, Carlo Mengoli, Giorgio Palù.   

Abstract

Patients undergoing radiotherapy for advanced cervical and endometrial cancer bear a considerable risk of developing vaginal preneoplastic lesions. Radiotherapy itself has been considered to have a role in the pathogenesis of vaginal dysplasia, although human papillomavirus (HPV) involvement has also been suggested. A series of 88 patients who underwent hysterectomy and were irradiated for gynecological cancer, including 43 with postradiation vaginal dysplasia at colposcopy and 45 without vaginal lesions, were included in this study. Detection and genotyping of HPV DNA in vaginal scraping were carried out by a PCR-based method and compared with colposcopic and cytological findings and with other clinical and laboratory data. Forty-two (97.7%) colposcopy-positive subjects and 6 (13.3%) colposcopically-negative patients were PCR-positive for high-risk HPV DNA (P < 0.000001). Twenty-two out of the 43 patients with colposcopic lesions showed an abnormal Papanicolau (PAP) test. Cytologic examination was negative in all colposcopically negative women. Type 16 HPV DNA was more frequent in patients with high-grade squamous intraepithelial lesions and in patients treated with external radiotherapy, whereas other types of high-risk HPV were more common in patients with low-grade lesions and in those treated with brachytherapy. When considering colposcopy as the standard for diagnosing vaginal dysplasia, HPV DNA testing was more sensitive than the PAP test. However, the specificity of the PAP test was higher with no false-positive case. In conclusion, vaginal preneoplastic changes in women post-hysterectomy and receiving radiotherapy for cervical, endometrial, and vaginal cancer represent an HPV-related nosologic entity. Whereas colposcopic examination can detect these preneoplastic lesions, HPV genotyping is a sensitive, inexpensive, and noninvasive method that may complement colposcopy and the PAP test. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116034     DOI: 10.1002/jmv.10077

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Risk factors for non-initiation of the human papillomavirus vaccine among adolescent survivors of childhood cancer.

Authors:  James L Klosky; Kathryn M Russell; Kristin E Canavera; Heather L Gammel; Jason R Hodges; Rebecca H Foster; Gilbert R Parra; Jessica L Simmons; Daniel M Green; Melissa M Hudson
Journal:  Cancer Prev Res (Phila)       Date:  2013-08-27

2.  Risky sexual behavior in adolescent survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  James L Klosky; Rebecca H Foster; Zhenghong Li; Courtney Peasant; Carrie R Howell; Ann C Mertens; Leslie L Robison; Kirsten K Ness
Journal:  Health Psychol       Date:  2013-12-23       Impact factor: 4.267

Review 3.  Human papillomavirus vaccination in survivors of childhood cancer.

Authors:  James L Klosky; Heather L Gamble; Sheri L Spunt; Mary E Randolph; Daniel M Green; Melissa M Hudson
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

4.  Cervicovaginal cytology in patients undergoing pelvic radiotherapy using the Focalpoint system: results from the RODEO study.

Authors:  Maíra Degiovani Stein; José Humberto T G Fregnani; Cristovam Scapulatempo-Neto; Adhemar Longatto-Filho
Journal:  Diagn Pathol       Date:  2015-01-16       Impact factor: 2.644

5.  Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period.

Authors:  Kuan-Der Lee; Chao-Yu Chen; Huei-Jean Huang; Ting-Yao Wang; David Teng; Shih-Hao Huang; Chyong-Huey Lai; Min-Chi Chen
Journal:  BMC Cancer       Date:  2015-05-11       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.